RIFAXIMIN by Novartis is [see clinical pharmacology ()]. Approved for travelers’ diarrhea (td) caused by noninvasive strains of escherichia coli in adults, older, irritable bowel syndrome with diarrhea (ibs-d) in adults.
Drug data last refreshed 18h ago
[see Clinical Pharmacology ()].
Worked on RIFAXIMIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
Rifaximin SSD in Dementia Trial
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis